Histological examination by an experienced pathologist is still essential and plays a crucial role in current medicine. In a very near future, HER2 testing will be an integral part of gastric carcinoma examination, namely in cases, where trastuzumab treatment is considered.
HER2 testing in gastric carcinoma is in some aspects specific - in particular its expression pattern, different from breast cancer, as well as modified quantitative criteria of positivity.